TAR-200,Cetrelimab,cisplatin
Janssen
['gu ', 'cisplatin']
 grateful to asco-gu for the opportunity to present the phase ii #sunrise4 trial - now accruing at &gt;95 centers globally! excited to advance our understanding of neoadjuvant options for our patients who cannot receive cisplatinum. 
Associate Professor & Uro-Oncologist at UW; Associate Editor at European Urology; Passionate about improving outcomes & QOL in GU Cancers & Surgical Education